TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8912763

Group type: EXPERIMENTAL
Intervention: Large-volume aspiration
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Low serum albumin (< 30 mg/dl)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Crude mortality rate
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pneumonia-related mortality
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Attributable mortality
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Prior swallowing disorders
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Body temperature on admission < 37 degrees C
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Respiratory frequency > 30/min
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Three or more affected lobes on chest radiograph
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 101
Study: 1991422

Group type: EXPERIMENTAL
Intervention: Incision, drainage and fistulectomy with primary partial internal sphincterectomy (group I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Incision and drainage alone (group II)
Number of subjects: 70
Study: 6408298

Group type: EXPERIMENTAL
Intervention: Synthetic secretin (0.25 clinical units/kg bw/h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Synthetic somatostatin (250 micrograms/h)
Number of subjects: 30
Study: 31937248

Group type: EXPERIMENTAL
Intervention: Pain (measured by Face Pain Scale, FPS, range 0-6) in the older group (65-79 years)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Pain (measured by Face Pain Scale, FPS, range 0-6) in the oldest-old group (80 years or older)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Recurrent falls in the older group (65-79 years)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Recurrent falls in the oldest-old group (80 years or older)
Number of subjects: 772
Study: 27701370

Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of iloprost (Endoprost®) after balloon angioplasty of below-the-knee vessels
Number of subjects: 32
Study: 26783035

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles injection around the primary tumor
Number of subjects: 114

Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 114
Study: 26934294

Group type: EXPERIMENTAL
Intervention: FACE-Q appearance scales measuring skin, lips, and facial rhytids (overall, forehead, glabella, lateral periorbital area, lips, marionette lines)
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: FACE-Q adverse effects checklists for problems after skin and lip treatment
Number of subjects: 783

Group type: COMPARATOR
Intervention: Pretreatment scores on 7 of the 8 appearance scales
Number of subjects: 783
Study: 24251724

Group type: EXPERIMENTAL
Intervention: Written pain neuroscience education
Number of subjects: 114

Group type: COMPARATOR
Intervention: Written relaxation training
Number of subjects: 114
Study: 23010601

Group type: EXPERIMENTAL
Intervention: SII RMab 10 IU/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRIG 20 IU/kg
Number of subjects: 0
Study: 19276403

Group type: EXPERIMENTAL
Intervention: Extensive, individualized cognitive/sensorimotor stimulation by public health nurses
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 62
Study: 18226292

Group type: EXPERIMENTAL
Intervention: MUFA olive oil-rich diet (38 % fat, 22 % MUFA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SFA-enriched diet (38 % fat, 20 % SFA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CHO-rich diet (30 % fat, < 10 % SFA, 55 % CHO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MUFA olive oil-rich diet
Number of subjects: 20
Study: 15298982

Group type: EXPERIMENTAL
Intervention: 1-hour submaximal aerobic exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Obese skeletal muscle
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lean skeletal muscle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Percentage of body fat and maximal oxygen uptake per kilogram of fat-free mass
Number of subjects: 16
Study: 12404672

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10204636

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7753268

Group type: EXPERIMENTAL
Intervention: Polysulfone membrane dialysis
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cuprophane membrane dialysis
Number of subjects: 26
Study: 2278333

Group type: EXPERIMENTAL
Intervention: Nasal pulse oximetry
Number of subjects: 10

Group type: COMPARATOR
Intervention: Finger pulse oximetry
Number of subjects: 10
Study: 6938018

Group type: EXPERIMENTAL
Intervention: Continuous oral therapy with estramustine phosphate (Estracyt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent oral therapy with estramustine phosphate (Estracyt)
Number of subjects: 0
Study: 30616675

Group type: EXPERIMENTAL
Intervention: Enteral sedation (hydroxyzine, lorazepam, melatonin)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Intravenous sedation (midazolam, propofol)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Enteral sedation
Number of subjects: 348

Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 348
Study: 27847368

Group type: EXPERIMENTAL
Intervention: Live attenuated cholera vaccine CVD 103-HgR (Vaxchora)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26352257

Group type: EXPERIMENTAL
Intervention: Delayed OSS (on-site support) after training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Immediate OSS (on-site support) after training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Extended OSS (three additional visits over six months)
Number of subjects: 36
Study: 23835735

Group type: EXPERIMENTAL
Intervention: Community-friendly Health Recovery Program (CHRP)
Number of subjects: 0
Study: 21157384

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg · kg(‐1))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Caffeine and Placebo
Number of subjects: 13
Study: 20031767

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1468
Study: 17142256

Group type: EXPERIMENTAL
Intervention: Audiotapes of conversations with a neonatologist (n=102)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (n=98)
Number of subjects: 200
Study: 14987586

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11320916

Group type: EXPERIMENTAL
Intervention: Palpable short saphenous vein (SSV) assessment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Not palpable short saphenous vein (SSV) assessment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Hand-held Doppler insonation (HHD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Combined tests (palpation and HHD)
Number of subjects: 160
Study: 9562003

Group type: EXPERIMENTAL
Intervention: Exercise training at 60% of peak oxygen uptake (Vo2) three times a week for 10 weeks (Group T)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Not applicable (Group C did not exercise)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Presence of hibernating myocardium assessed by LDSE
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pre‐to‐posttraining difference in LVEF at peak dobutamine infusion
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Presence of a viable response at baseline
Number of subjects: 71
Study: 8148354

Group type: EXPERIMENTAL
Intervention: Linoleate-enriched diet with 1200 mg/d of alpha-tocopherol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oleate-enriched diet with 1200 mg/d of alpha-tocopherol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard diet with 1200 mg/d of alpha-tocopherol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buoyant LDL from all subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dense LDL from linoleate group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dense LDL from oleate diet group
Number of subjects: 0
Study: 3130259

Group type: EXPERIMENTAL
Intervention: 2 g calcium added daily for 6‐7 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Calcium loading
Number of subjects: 14
Study: 31383436

Group type: EXPERIMENTAL
Intervention: Mindfulness and Emotional Intelligence Program (PINEP) - 12 sessions lasting an hour and a half
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 89
Study: 27784415

Group type: EXPERIMENTAL
Intervention: APAP (System One RemStar Auto A-Flex)
Number of subjects: 61

Group type: COMPARATOR
Intervention: CPAP (manually titrated, fixed pressure)
Number of subjects: 61
Study: 25835443

Group type: EXPERIMENTAL
Intervention: Denervation
Number of subjects: 361

Group type: COMPARATOR
Intervention: Sham procedure (non-crossover)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Sham procedure (crossover)
Number of subjects: 361
Study: 23131594

Group type: EXPERIMENTAL
Intervention: Endocavitary brachytherapy (EBT) boost for T1,2N+ tumors
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: EBT or stereotactic radiation boost for T3,4 tumors
Number of subjects: 411
Study: 21238531

Group type: EXPERIMENTAL
Intervention: GaAlAs laser at 8.5J/cm(2) energy density
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 0.25W, 20Hz, 0% water, 10% air
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study: 18447210

Group type: EXPERIMENTAL
Intervention: Head penetration needling group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine acupuncture group
Number of subjects: 71
Study: 16799310

Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fine mesh gauze treated with Furacin
Number of subjects: 40
Study: 12684301

Group type: EXPERIMENTAL
Intervention: Nasal pillows (Breeze; Mallinckrodt Corporation; Minneapolis, MN)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nasal mask (Contour; Respironics; Murrysville, PA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nasal pillows
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 39
Study: 10866905

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg. kg(‐1). min(‐1) IV during induction, reduced to 0.25 microg. kg(‐1). min(‐1) after intubation)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fentanyl (dose per usual practice of the anesthesiologist)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 103
Study: 9396415

Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) pacing alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) pacing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Right Ventricular Apex (RVA) pacing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Right Ventricular Outflow Tract (RVOT) pacing
Number of subjects: 27
Study: 1286654

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (AE) at 70% heart rate reserve for 40 minutes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 48
Study: 2580180

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice a day + Hydrochlorothiazide 25 mg once or twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice a day + Hydrochlorothiazide 25 mg once or twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg once daily + Hydrochlorothiazide 25 mg once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Captopril and Hydrochlorothiazide (long-term treatment, 11 months)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Captopril and Hydrochlorothiazide
Number of subjects: 22
Study: 31002614

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-PRF (conventional placement)
Number of subjects: 10
Study: 27964728

Group type: EXPERIMENTAL
Intervention: Organophosphate (chlorpyrifos 50% plus cypermethrin 5%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of organophosphate to placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both organophosphate and placebo
Number of subjects: 42
Study: 24141953

Group type: EXPERIMENTAL
Intervention: Percutaneous cervical discectomy (PCD)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Percutaneous cervical disc nucleoplasty (PCN)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Combination of PCD and PCN (PCDN)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 171
Study: 22571225

Group type: EXPERIMENTAL
Intervention: Non-surgical debridement with systemic Azithromax (®) for 4 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-surgical debridement without systemic antibiotics
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Non-surgical debridement with or without systemic antibiotics
Number of subjects: 48
Study: 20685496

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/Paracetamol 1000 mg
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg/Paracetamol 500 mg
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 18394014

Group type: EXPERIMENTAL
Intervention: Low-dose HT (1 mg of 17beta-estradiol and 0.5 mg of NETA)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Conventional-dose HT (2 mg of 17beta-estradiol and 1 mg of NETA)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 202
Study: 16166814

Group type: EXPERIMENTAL
Intervention: Radiotherapy (45 Gy)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chemotherapy (six cycles of CHOP every 21 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 96
Study: 14618037

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: On-pump CABG (n = 100)
Number of subjects: 200
Study: 10985613

Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg 3 times/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nalidixic acid 400 mg twice a day for 10 d
Number of subjects: 20
Study: 9057077

Group type: EXPERIMENTAL
Intervention: Dobutamine (2.5-7.5 micrograms/kg body weight per min, n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: OPC-18790 (5-10 micrograms/kg body weight per min, n = 9)
Number of subjects: 17
Study: 1394348

Group type: EXPERIMENTAL
Intervention: SR-diltiazem (120 mgs bid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3882657

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate, 1.5 g, administered orally 1 hour before extraction
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate, 1.5 g
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate and placebo
Number of subjects: 109
Study: 31236826

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy Group Prenatal Care (GPC) (N=498)
Number of subjects: 992

Group type: COMPARATOR
Intervention: Individual Prenatal Care (IPC) (N=994)
Number of subjects: 992
Study: 29683850

Group type: EXPERIMENTAL
Intervention: Lottery-based incentives (low-cost)
Number of subjects: 2532

Group type: COMPARATOR
Intervention: Gain-framed incentives (low-cost)
Number of subjects: 2532

Group type: EXPERIMENTAL
Intervention: Lottery-based incentives (high-cost)
Number of subjects: 2532

Group type: COMPARATOR
Intervention: Gain-framed incentives (high-cost)
Number of subjects: 2532

Group type: EXPERIMENTAL
Intervention: Loss-framed incentives (low-cost)
Number of subjects: 2532

Group type: EXPERIMENTAL
Intervention: Loss-framed incentives (high-cost)
Number of subjects: 2532
Study: 26260784

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 48

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 48
Study: 25161026

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22400174

Group type: EXPERIMENTAL
Intervention: Carbohydrate disorders (group I)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 112
Study: 20478333

Group type: COMPARATOR
Intervention: Internet
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: InPerson
Number of subjects: 481

Group type: COMPARATOR
Intervention: Hybrid
Number of subjects: 481
Study: 17826278

Group type: EXPERIMENTAL
Intervention: Digital preoperative planning
Number of subjects: 210

Group type: COMPARATOR
Intervention: Analogue preoperative planning
Number of subjects: 210
Study: 11768839

Group type: EXPERIMENTAL
Intervention: Oral tolterodine 2 mg BID (on days 1-14)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose combination oral contraceptive (ethinyl estradiol 30 microg/levonorgestrel 150 microg)
Number of subjects: 24
Study: 9244152

Group type: EXPERIMENTAL
Intervention: AM‐C10 (ampicillin suppositories with sodium caprate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: AM (ampicillin suppositories without sodium caprate)
Number of subjects: 12
Study: 8290903

Group type: EXPERIMENTAL
Intervention: Cefpirome
Number of subjects: 378

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 378

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 378
Study: 3030089

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 20
Study: 29973307

Group type: EXPERIMENTAL
Intervention: Incentive (intervention plus incentive; CAD $5.00 e‐gift card delivered weekly for completing action plans over 4 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Incentive (intervention plus incentive)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (intervention only)
Number of subjects: 69
Study: 27871269

Group type: EXPERIMENTAL
Intervention: Institutionalization of postpartum intrauterine device (IUD) training as part of OB/GYN training programs in intervention hospitals.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FIGO intervention for PPIUD training and integration into standard practice.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of PPIUD services in study hospitals.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nested mixed-methods performance evaluation.
Number of subjects: 0
Study: 26321559

Group type: EXPERIMENTAL
Intervention: Lateral plantar nerve release with calcaneal drilling (group 1, n=18)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Lateral plantar nerve release without calcaneal drilling (group 2, n=15)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lateral plantar nerve release with calcaneal drilling (group 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Lateral plantar nerve release without calcaneal drilling (group 2)
Number of subjects: 33
Study: 23988242

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted lens fragmentation and anterior capsulotomy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Manual cataract surgery
Number of subjects: 119
Study: 21170857

Group type: EXPERIMENTAL
Intervention: Open transvesical prostatectomy (OP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study: 18799429

Group type: EXPERIMENTAL
Intervention: Stress (public-speaking task)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study: 16822128

Group type: EXPERIMENTAL
Intervention: Masked prime stimuli with short intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked prime stimuli with long intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global-level priming effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local-level effects
Number of subjects: 0
Study: 12814613

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10634375

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Recombinant human GH treatment (0.15 IU/kg x day for 1 week)
Number of subjects: 17
Study: 8775589

Group type: EXPERIMENTAL
Intervention: Active treatment (encainide or flecainide)
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1153
Study: 1295821

Group type: EXPERIMENTAL
Intervention: GH regimen of 15 IU/m2/week administered as a daily subcutaneous injection (26 males, 1 female)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GH regimen of 30 IU/m2/week administered as a daily subcutaneous injection (20 males, 5 females)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GH regimen of 25 IU/m2/week administered as a daily subcutaneous injection (16 short normal children, 9 males, 7 females)
Number of subjects: 52
Study: 31955812

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: LGE presence
Number of subjects: 252
Study: 31390305

Group type: EXPERIMENTAL
Intervention: Kinect-based educational games (Fruits) played once a week for 5 weeks in addition to standard treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 10